(Sharecast News) - Drugmaker GSK reported new early‑stage global data for risvutatug rezetecan (Ris‑Rez), an experimental cancer treatment being tested in patients with relapsed small‑cell lung cancer.
In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg....

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE